Jaguar Health Partners with Andelyn to Advance Gene Therapy for SHANK3-Related Autism

Jaguar Health and Andelyn Biosciences Join Forces to Tackle SHANK3-Related Autism

Jaguar Health makes a significant advancement in the field of gene therapy through its recent partnership with Andelyn Biosciences. This collaboration aims to enhance the late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, an investigational gene therapy designed to address SHANK3 haploinsufficiency, a genetic condition associated with Phelan-McDermid syndrome (PMS). PMS is a severe neurodevelopmental disorder that leads to cognitive impairments, communication difficulties, and necessitates continuous care. Currently, no effective medications exist to treat the root causes of PMS, underscoring the critical need for innovative therapies that target the condition at its source.

The focus of JAG201 is to utilize an adeno-associated virus (AAV) vector, specifically AAV9, to deliver a functional SHANK3 minigene directly to neurons in the central nervous system. By restoring synaptic function, this therapy aims to improve cognitive and motor skills in affected individuals. Andelyn Biosciences brings valuable expertise in AAV vector manufacturing and Good Manufacturing Practices (GMP) to this partnership, which will be crucial in advancing JAG201 toward commercial readiness. Both companies highlight their shared commitment to accelerating the development of gene therapies that can offer real hope to patients who currently have few to no therapeutic options available.

This collaboration is particularly significant as it addresses the pressing unmet medical needs of those affected by SHANK3-related autism and PMS. Experts from both organizations, including Matt Niloff of Andelyn and Rob Mancino of Jaguar, emphasize the importance of their combined efforts in transitioning promising therapies from laboratory research to clinical application. This partnership not only represents a strategic move for Jaguar Health but also embodies a broader commitment within the biotechnology industry to innovate and deliver solutions for some of the most challenging health conditions.

In addition to the partnership, Jaguar Health continues to prioritize the development of therapies that address specific unmet needs in the patient population. By focusing on genetic disorders such as PMS, the company positions itself at the forefront of a rapidly evolving landscape in gene therapy, which holds the potential to transform treatment paradigms for various conditions.

As the collaboration progresses, it signals a hopeful direction for patients and families affected by SHANK3 haploinsufficiency, promising advancements in both scientific understanding and therapeutic options.